Nathalie Adda is VP at ENANTA PHARMACEUTICALS INC (ENTA). They have made 12 open-market trades across 1 company since 2018, most recently 2022-04-04.
CIK 0001646976
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ENTA | 34,982 | $389K |
Shares reported on the most recent Form 4, priced at the 2022-04-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ENTA | SELL | 2022-04-01 | 2022-04-05 | $71.62 | $11.8M | -2.4% | -17.5% | -27.1% |
| ENTA | SELL | 2022-03-01 | 2022-03-03 | $70.20 | $5.2M | -2.7% | +9.6% | -40.3% |
| ENTA | SELL | 2022-01-11 | 2022-01-13 | $70.13 | $1.8M | -5.7% | +0.3% | +23.6% |
| ENTA | SELL | 2021-12-01 | 2021-12-03 | $86.13 | $1.9M | -11.6% | -10.2% | -17.4% |
| ENTA | SELL | 2021-11-01 | 2021-11-02 | $84.88 | $1.6M | +5.4% | -2.7% | -31.4% |
| ENTA | SELL | 2021-10-08 | 2021-10-13 | $70.15 | $2.5M | +8.4% | +30.7% | +1.1% |
| ENTA | SELL | 2018-09-20 | 2018-09-21 | $95.56 | $703K | -8.7% | -13.5% | -25.4% |
| ENTA | SELL | 2018-08-20 | 2018-08-21 | $92.40 | $703K | -1.5% | +5.8% | -15.2% |
| ENTA | SELL | 2018-07-18 | 2018-09-21 | $124.84 | $611K | -8.7% | -13.5% | -25.4% |
| ENTA | SELL | 2018-06-18 | 2018-06-19 | $114.85 | $954K | +0.6% | +6.9% | -20.4% |
| ENTA | SELL | 2018-05-16 | 2018-05-18 | $105.39 | $749K | -4.5% | +9.1% | -14.4% |
| ENTA | SELL | 2018-04-16 | 2018-04-18 | $85.57 | $362K | +7.1% | +20.2% | +42.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.